Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 19/20 | 0.87 |
| ▸ | PDE5A | O76074 | 5/20 | 0.87 |
| ▸ | PDE3B | Q13370 | 5/20 | 0.87 |
| ▸ | PDE11A | Q9HCR9 | 5/20 | 0.87 |
| ▸ | PDE7B | Q9NP56 | 5/20 | 0.87 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.87 |
| ▸ | PDE2A | O00408 | 4/20 | 0.87 |
| ▸ | PDE8A | O60658 | 4/20 | 0.87 |
| ▸ | PDE9A | O76083 | 3/20 | 0.81 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.70 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.70 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.70 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10201366 | 0.97 | PDE4A (0.92) | PDE4APDE5APDE3BPDE11APDE7B | |
| SCHEMBL19134017 | 0.93 | PDE4A (1.00) | PDE4APDE5APDE3BPDE11APDE7B | |
| SCHEMBL4920743 | 0.93 | PDE4A (1.00) | PDE4APDE5APDE3BPDE11APDE7B | |
| SCHEMBL8048554 | 0.91 | PDE4A (0.84) | PDE4APDE5APDE3BPDE11APDE7B | |
| SCHEMBL17366408 | 0.91 | PDE4A (0.84) | PDE4APDE5APDE3BPDE11APDE7B | |
| SCHEMBL8058077 | 0.91 | PDE4A (0.86) | PDE4APDE5APDE3BPDE11APDE7B | |
| SCHEMBL4912869 | 0.90 | PDE4A (1.00) | PDE4APDE5APDE3BPDE11APDE7B | |
| SCHEMBL19134015 | 0.90 | PDE4A (1.00) | PDE4APDE5APDE3BPDE11APDE7B | |
| SCHEMBL10201377 | 0.90 | PDE4A (0.81) | PDE4APDE5APDE3BPDE11APDE7B | |
| SCHEMBL18380625 | 0.90 | PDE4A (0.80) | PDE4APDE5APDE3BPDE11APDE7B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9545406-B2 | Method of treating a CNS injury with a PDE1 inhibitor | INTRA-CELLULAR THERAPIES, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-20160038494-A1 | NOVEL COMBINATION | INTRA-CELLULAR THERAPIES, INC. | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160038494-A1 | NOVEL COMBINATION | PDE5A, PDE2A, PDE3A | PDE4A 9/4885PDE5A 1/4885PDE3B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.